EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Adult cardiomyocytes‐derived EVs for the treatment of cardiac fibrosis

Marta Prieto-Vila, Yusuke Yoshioka, Naoya Kuriyama, Akihiko Okamura, Yusuke Yamamoto, Asao Muranaka, Takahiro Ochiya iD

Journal of Extracellular Vesicles · 2024-07 · 13 (7)

DOI: 10.1002/jev2.12461 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 28.06.2024. Verfasst von Marta Prieto-Vila und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Medicine, Tokyo Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Extracellular Vesicles, Fibrosis. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac fibrosis is a common pathological feature of cardiovascular diseases that arises from the hyperactivation of fibroblasts and excessive extracellular matrix (ECM) deposition, leading to impaired cardiac function and potentially heart failure or arrhythmia. Extracellular vesicles (EVs) released by cardiomyocytes (CMs) regulate various physiological functions essential for myocardial homeostasis, which are disrupted in cardiac disease. Therefore, healthy CM‐derived EVs represent a promising cell‐free therapy for the treatment of cardiac fibrosis. To this end, we optimized the culture conditions of human adult CMs to obtain a large yield of EVs without compromising cellular integrity by using a defined combination of small molecules. EVs were isolated by ultracentrifugation, and their characteristics were analysed. Finally, their effect on fibrosis was tested. Treatment of TGFβ‐activated human cardiac fibroblasts with EVs derived from CMs using our culture system resulted in a decrease in fibroblast activation markers and ECM accumulation. The rescued phenotype was associated with specific EV cargo, including multiple myocyte‐specific and antifibrotic microRNAs, although their effect individually was not as effective as the EV treatment. Notably, pathway analysis showed that EV treatment reverted the transcription of activated fibroblasts and decreased several signalling pathways, including MAPK, mTOR, JAK/STAT, TGFβ, and PI3K/Akt, all of which are involved in fibrosis development. Intracardiac injection of CM‐derived EVs in an animal model of cardiac fibrosis reduced fibrotic area and increased angiogenesis, which correlated with improved cardiac function. These findings suggest that EVs derived from human adult CMs may offer a targeted and effective treatment for cardiac fibrosis, owing to their antifibrotic properties and the specificity of cargo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocytes, CardiacExtracellular VesiclesFibrosisHumansFibroblastsAnimalsMicroRNAsExtracellular MatrixSignal TransductionTransforming Growth Factor betaCells, CulturedMiceAdult

Stichwörter der Autor:innen

EVscardiac fibrosiscardiovascular diseasescell‐free therapyextracellular vesiclesmicroRNA

Substanzen

MicroRNAsTransforming Growth Factor beta

Autor:innen und Institutionen

  • Department of Molecular and Cellular Medicine, Tokyo Medical University, Tokyo, Japan.
  • Department of Vascular Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
  • Department of Cardiovascular Medicine, Nara Medical University, Nara, Japan.
  • Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.

ORCID-Profile: Takahiro Ochiya

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Prieto-Vila, M., Yoshioka, Y., Kuriyama, N., Okamura, A., Yamamoto, Y., Muranaka, A., & Ochiya, T. (2024). Adult cardiomyocytes‐derived EVs for the treatment of cardiac fibrosis. Journal of Extracellular Vesicles, 13(7). https://doi.org/10.1002/jev2.12461

Vancouver

Prieto-Vila M, Yoshioka Y, Kuriyama N, Okamura A, Yamamoto Y, Muranaka A, et al. Adult cardiomyocytes‐derived EVs for the treatment of cardiac fibrosis. Journal of Extracellular Vesicles. 2024;13(7). doi:10.1002/jev2.12461

BibTeX
@article{PrietoVila2024,
  author = {Prieto-Vila, Marta and Yoshioka, Yusuke and Kuriyama, Naoya and Okamura, Akihiko and Yamamoto, Yusuke and Muranaka, Asao and Ochiya, Takahiro},
  title = {Adult cardiomyocytes‐derived EVs for the treatment of cardiac fibrosis},
  journal = {Journal of Extracellular Vesicles},
  year = {2024},
  volume = {13},
  number = {7},
  doi = {10.1002/jev2.12461}
}
Kostenlos starten →